Ghaderian Mehdi, Merajie Mahmood, Mortezaeian Hodjjat, Aarabi Moghadam Mohammad Yoosef, Shah Mohammadi Akbar
Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. ; Shaheed Rajaie Cardiovascular, Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
Shaheed Rajaie Cardiovascular, Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
J Tehran Heart Cent. 2015 Oct 27;10(4):182-7.
The ventricular septal defect (VSD) is the most common form of congenital heart defects. The purpose of this study was to evaluate the results of the early complications and mid-term follow-up of the transcatheter closure of the VSD using the Amplatzer VSD Occluder.
Between April 2012 and October 2013, 110 patients underwent the percutaneous closure of the perimembranous VSD. During the procedure, the size and type of the VSD were obtained via ventriculography. A device at least 2 mm larger than the VSD diameter measured via ventriculography was deployed. The size of the VSD, size of the Amplatzer, and device-size to VSD-size ratio were calculated. After the confirmation of the suitable position of the device via echocardiography and left ventriculography, the device was released. Follow-up evaluations were done at discharge as well as at 1, 6, and 12 months and yearly thereafter for the VSD occlusion and complete heart block.
The study population comprised 62 females and 48 males. The mean age and weight of the patients at procedure were 4.3 ± 5.6 years (range: 2 to 14) and 14.9 ± 10.8 kg (range: 10 to 43). The average device size was 7.0 ± 2.5 mm (range: 4 to 14). The VSD occlusion rate was 72.8% at the completion of the procedure and rose up to 99.0% during the follow-up. The most serious significant complication was complete atrioventricular block, which was seen in 2 patients. The mean follow-up duration was 10.9 ± 3.6 months.
The transcatheter closure of the perimembranous VSD was a safe and effective treatment with excellent closure rates in our study population. This procedure had neither mortality nor serious complications.
室间隔缺损（VSD）是先天性心脏缺陷最常见的形式。本研究的目的是评估使用Amplatzer室间隔缺损封堵器经导管封堵室间隔缺损的早期并发症及中期随访结果。
2012年4月至2013年10月期间，110例患者接受了经皮膜周部室间隔缺损封堵术。在手术过程中，通过心室造影确定室间隔缺损的大小和类型。部署一个比通过心室造影测量的室间隔缺损直径至少大2 mm的装置。计算室间隔缺损的大小、Amplatzer装置的大小以及装置大小与室间隔缺损大小的比值。经超声心动图和左心室造影确认装置位置合适后，释放装置。出院时以及术后1、6和12个月及此后每年进行随访评估，观察室间隔缺损封堵情况及是否发生完全性心脏传导阻滞。
研究人群包括62名女性和48名男性。手术时患者的平均年龄和体重分别为4.3±5.6岁（范围：2至14岁）和14.9±10.8 kg（范围：10至43 kg）。平均装置大小为7.0±2.5 mm（范围：4至14 mm）。手术结束时室间隔缺损封堵率为72.8%，随访期间升至99.0%。最严重的并发症是完全性房室传导阻滞，有2例患者出现。平均随访时间为10.9±3.6个月。
在我们的研究人群中，经导管封堵膜周部室间隔缺损是一种安全有效的治疗方法，封堵率极佳。该手术无死亡病例，也无严重并发症。
